{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:23Z","timestamp":1792852703192,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40119-024-00379-0","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T03:24:19Z","timestamp":1723865059000},"page":"645-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Milvexian: An Oral, Bioavailable Factor XIa Inhibitor"],"prefix":"10.1007","volume":"13","author":[{"given":"Shyon","family":"Parsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha S.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olu","family":"Akinrimisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"issue":"6","key":"379_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.17156","volume":"6","author":"JA Rymer","year":"2023","unstructured":"Rymer JA, Chiswell K, Young L, et al. Analysis of oral anticoagulant dosing and adherence to therapy among patients with nonvalvular atrial fibrillation. JAMA Netw Open. 2023;6(6): e2317156. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.17156.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"379_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","volume":"40","author":"S Ballestri","year":"2023","unstructured":"Ballestri S, Romagnoli E, Arioli D, et al. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther. 2023;40(1):41\u201366. https:\/\/doi.org\/10.1007\/s12325-022-02333-9.","journal-title":"Adv Ther"},{"issue":"2","key":"379_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.120.007230","volume":"14","author":"CA Jackevicius","year":"2021","unstructured":"Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021;14(2): e007230. https:\/\/doi.org\/10.1161\/circoutcomes.120.007230.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"379_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1160\/TH10-05-0307","volume":"105","author":"O Salomon","year":"2011","unstructured":"Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105(2):269\u201373. https:\/\/doi.org\/10.1160\/TH10-05-0307.","journal-title":"Thromb Haemost"},{"issue":"8","key":"379_CR5","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","volume":"111","author":"O Salomon","year":"2008","unstructured":"Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111(8):4113\u20137. https:\/\/doi.org\/10.1182\/blood-2007-10-120139.","journal-title":"Blood"},{"issue":"9","key":"379_CR6","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210\u20135. https:\/\/doi.org\/10.1182\/blood-2016-09-742262.","journal-title":"Blood"},{"issue":"10","key":"379_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM200003093421004","volume":"342","author":"JCM Meijers","year":"2000","unstructured":"Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696\u2013701. https:\/\/doi.org\/10.1056\/NEJM200003093421004.","journal-title":"N Engl J Med"},{"issue":"2","key":"379_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cts.13148","volume":"15","author":"V Perera","year":"2022","unstructured":"Perera V, Wang Z, Luettgen J, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15(2):330\u201342. https:\/\/doi.org\/10.1111\/cts.13148.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"379_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","volume":"81","author":"J Harrington","year":"2023","unstructured":"Harrington J, Piccini JP, Alexander JH, Granger CB, Patel MR. Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week. J Am Coll Cardiol. 2023;81(8):771\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.057.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"379_CR10","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1182\/blood-2012-07-292094","volume":"120","author":"T Renn\u00e9","year":"2012","unstructured":"Renn\u00e9 T, Schmaier AH, Nickel KF, Blomb\u00e4ck M, Maas C. In vivo roles of factor XII. Blood. 2012;120(22):4296\u2013303. https:\/\/doi.org\/10.1182\/blood-2012-07-292094.","journal-title":"Blood"},{"key":"379_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.903029","volume":"9","author":"S Nopp","year":"2022","unstructured":"Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence. Front Cardiovasc Med. 2022;9: 903029. https:\/\/doi.org\/10.3389\/fcvm.2022.903029.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"379_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","volume":"39","author":"SP Grover","year":"2019","unstructured":"Grover SP, Mackman N. Intrinsic pathway of coagulation and thrombosis. Arterioscler Thromb Vasc Biol. 2019;39(3):331\u20138. https:\/\/doi.org\/10.1161\/ATVBAHA.118.312130.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"379_CR13","first-page":"319","volume":"11","author":"MH Periayah","year":"2017","unstructured":"Periayah MH, Halim AS, Mat Saad AZ. Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. Int J Hematol Oncol Stem Cell Res. 2017;11(4):319\u201327.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"3","key":"379_CR14","doi-asserted-by":"publisher","first-page":"C365","DOI":"10.1152\/ajpcell.00056.2020","volume":"320","author":"SE Reitsma","year":"2021","unstructured":"Reitsma SE, Pang J, Raghunathan V, et al. Role of platelets in regulating activated coagulation factor XI activity. Am J Physiol Cell Physiol. 2021;320(3):C365\u201374. https:\/\/doi.org\/10.1152\/ajpcell.00056.2020.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"379_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.01.011","volume":"21","author":"S Uchiyama","year":"2012","unstructured":"Uchiyama S, Ibayashi S, Matsumoto M, et al. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis. 2012;21(3):165\u201373. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2012.01.011.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"11","key":"379_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"2","key":"379_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/01.cir.84.2.527","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Study","year":"1991","unstructured":"Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527\u201339. https:\/\/doi.org\/10.1161\/01.cir.84.2.527.","journal-title":"Circulation"},{"issue":"12","key":"379_CR18","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"10","key":"379_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"8","key":"379_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28033","volume":"6","author":"MC Fang","year":"2023","unstructured":"Fang MC, Reynolds K, Fan D, et al. Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism. JAMA Netw Open. 2023;6(8): e2328033. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.28033.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"379_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355.","journal-title":"Circulation"},{"key":"379_CR22","unstructured":"PubChem. Milvexian. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/118277544. Accessed 3 Sep 2023."},{"key":"379_CR23","doi-asserted-by":"publisher","unstructured":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00613.","DOI":"10.1021\/acs.jmedchem.1c00613"},{"issue":"9","key":"379_CR24","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","volume":"4","author":"X Wang","year":"2006","unstructured":"Wang X, Smith PL, Hsu MY, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006;4(9):1982\u20138. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02093.x.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"379_CR25","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1055\/s-0037-1613081","volume":"87","author":"ED Rosen","year":"2002","unstructured":"Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thrombosis Haemostasis. 2002;87(4):774\u20136.","journal-title":"Thrombosis Haemostasis."},{"issue":"4","key":"379_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","volume":"3","author":"X Wang","year":"2005","unstructured":"Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3(4):695\u2013702. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01236.x.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"379_CR27","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1055\/a-2061-3311","volume":"7","author":"X Wang","year":"2023","unstructured":"Wang X, Li Q, Du F, Shukla N, Nawrocki AR, Chintala M. Antithrombotic effects of the novel small-molecule factor XIa inhibitor milvexian in a rabbit arteriovenous shunt model of venous thrombosis. TH Open. 2023;7(2):e97\u2013104. https:\/\/doi.org\/10.1055\/a-2061-3311.","journal-title":"TH Open"},{"key":"379_CR28","unstructured":"Small-Molecule Factor XIa Inhibitor, BMS-986177\/JNJ-70033093, prevents and treats arterial thrombosis in rabbits at doses that preserve hemostasis. ISTH Congress Abstracts. https:\/\/abstracts.isth.org\/abstract\/small-molecule-factor-xia-inhibitor-bms-986177-jnj-70033093-prevents-and-treats-arterial-thrombosis-in-rabbits-at-doses-that-preserve-hemostasis\/. Accessed 3 Sep 2023."},{"key":"379_CR29","unstructured":"Bristol-Myers Squibb. A study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of BMS-986177 in Healthy Subjects. clinicaltrials.gov; 2017. https:\/\/clinicaltrials.gov\/study\/NCT02608970. Accessed 1 Sep 2023."},{"key":"379_CR30","unstructured":"Janssen Research & Development, LLC. An Open-Label, Randomized, Crossover Study to Evaluate the Relative Oral Bioavailability, Pharmacokinetics, and Food Effect After Single Dose (for Part 1, Part 3, Part 4 and Part 5) or Multiple-Dose (for Part 2) Administration of JNJ-70033093 (Milvexian) in Healthy Adult Participants Using Tablet, Capsule and Dispersed Tablet Formulations. clinicaltrials.gov; 2022. Accessed September 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04844424. Accessed 1 Sep 2023."},{"issue":"23","key":"379_CR31","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2113194.","journal-title":"N Engl J Med"},{"key":"379_CR32","unstructured":"Antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. American College of Cardiology. Accessed September 3, 2023. https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2022\/08\/27\/04\/12\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fClinical-Trials%2f2022%2f08%2f27%2f04%2f12%2fAXIOMATIC-SSP. Accessed 3 Sep 2023."},{"issue":"10","key":"379_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106742","volume":"31","author":"M Sharma","year":"2022","unstructured":"Sharma M, Molina CA, Toyoda K, et al. Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis. 2022;31(10): 106742. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2022.106742.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"379_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma M, Molina CA, Toyoda K, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23(1):46\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(23)00403-9.","journal-title":"Lancet Neurol"},{"issue":"11","key":"379_CR35","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/01.str.25.11.2220","volume":"25","author":"P Lyden","year":"1994","unstructured":"Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH stroke scale using video training NINDS TPA stroke study group. Stroke. 1994;25(11):2220\u20136. https:\/\/doi.org\/10.1161\/01.str.25.11.2220.","journal-title":"Stroke"},{"issue":"9558","key":"379_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(07)60150-0","volume":"369","author":"SC Johnston","year":"2007","unstructured":"Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369(9558):283\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(07)60150-0.","journal-title":"Lancet"},{"key":"379_CR37","unstructured":"Standardized Bleeding Definitions for Cardiovascular Clinical Trials | Circulation. Accessed September 7, 2023. https:\/\/www.ahajournals.org\/doi\/10.1161\/circulationaha.110.009449. Accessed 7 Sep 2023."},{"issue":"11","key":"379_CR38","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1111\/jth.15048","volume":"18","author":"L Franco","year":"2020","unstructured":"Franco L, Becattini C, Beyer-Westendorf J, et al. Definition of major bleeding: prognostic classification. J Thromb Haemost. 2020;18(11):2852\u201360. https:\/\/doi.org\/10.1111\/jth.15048.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"379_CR39","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"key":"379_CR40","unstructured":"Janssen Research & Development, LLC. A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to demonstrate the efficacy and safety of Milvexian, an oral factor XIa inhibitor, for stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack. clinicaltrials.gov; 2023. Accessed September 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05702034. Accessed 1 Sep 2023."},{"key":"379_CR41","unstructured":"Janssen Research & Development, LLC. A phase 3, randomized, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of milvexian, an oral factor XIa inhibitor, after a recent acute coronary syndrome. clinicaltrials.gov; 2023. Accessed September 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05754957. Accessed 1 Sep 2023."},{"key":"379_CR42","unstructured":"Janssen Research & Development, LLC. A phase 3, randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian, an oral factor XIa inhibitor, versus apixaban in participants with atrial fibrillation. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05757869. Accessed 1 Sep 2023."},{"issue":"21","key":"379_CR43","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.3390\/jcm11216314","volume":"11","author":"E Campello","year":"2022","unstructured":"Campello E, Simioni P, Prandoni P, Ferri N. Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders. J Clin Med. 2022;11(21):6314. https:\/\/doi.org\/10.3390\/jcm11216314.","journal-title":"J Clin Med"},{"issue":"10333","key":"379_CR44","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet. 2022;399(10333):1383\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1.","journal-title":"The Lancet"},{"issue":"10357","key":"379_CR45","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. 2022;400(10357):997\u20131007. https:\/\/doi.org\/10.1016\/S0140-6736(22)01588-4.","journal-title":"The Lancet"},{"issue":"16","key":"379_CR46","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","volume":"146","author":"SV Rao","year":"2022","unstructured":"Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196\u2013206. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061612.","journal-title":"Circulation"},{"key":"379_CR47","unstructured":"OCEANIC-AF study stopped early due to lack of efficacy. OCEANIC-AF study stopped early due to lack of efficacy. https:\/\/www.bayer.com\/media\/en-us\/oceanic-af-study-stopped-early-due-to-lack-of-efficacy\/. Accessed 15 Jan 2024."},{"issue":"7","key":"379_CR48","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385(7):609\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2105872.","journal-title":"N Engl J Med"},{"issue":"2","key":"379_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323(2):130\u20139. https:\/\/doi.org\/10.1001\/jama.2019.20687.","journal-title":"JAMA"},{"issue":"22","key":"379_CR50","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","volume":"138","author":"CU Lorentz","year":"2021","unstructured":"Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138(22):2173\u201384. https:\/\/doi.org\/10.1182\/blood.2021011725.","journal-title":"Blood"},{"issue":"3","key":"379_CR51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1405760.","journal-title":"N Engl J Med"},{"issue":"2","key":"379_CR52","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2021","unstructured":"Walsh M, Bethune C, Smyth A, et al. Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep. 2021;7(2):200\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.011.","journal-title":"Kidney Int Rep"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-024-00379-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T17:06:43Z","timestamp":1732900003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-024-00379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1007\/s40119-024-00379-0","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sneha S. Jain reports consulting fees from Bristol Myers Squibb, ARTIS Ventures, and Broadview Ventures outside of the submitted work.    Carolyn S. P. Lam      is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has served as consultant or on the Advisory Board\/Steering Committee\/Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Hanmi, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape\/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Kenneth W. Mahaffey is supported by the American Heart Association, Apple Inc., Bayer Pharmaceuticals, the California Institute for Regenerative Medicine, Commonwealth Serum Laboratories (CSL), Eldos, Gilead, Idorsia, Johnson & Johnson (J&J), Luitpold, Novartis, the PAC-12, Precondior, Sanifit, and Verily (Google). He reports consulting fees from Applied Therapeutics, Bayer, Bristol Meyer Squibb, BridgeBio, CSL Behring, Elsevier, Fuson, Human, J&J, Moderna, Myokardia, Novartis, Novo Nordisk, Otsuka, Phasebio, Portola, Quidel, and Theravance. He reports equity holdings in Human, Medeloop, Precordior, and Regencor. Kenneth W. Mahaffey is an editorial board member of Cardiology and Therapy. Kenneth W. Mahaffey was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Shyon Parsa has nothing to disclose. Olu Akinrimsi has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}